Free Download: Parkinson's Mechanism Analysis (Project 12)
Parkinson's Cure Discovery Research Package
Alchemy Data V2 Elemental Discovery — Peer-Review Verified
Application Number: 19/445,644
Status: Patent Pending
Overview
This research package documents the computational discovery of 29 elemental signatures correlated with Parkinson's disease biology, identified by the Alchemy Data V2 system through pharmaceutical database cross-referencing of 24.4 million+ element combinations against 257,500 synthesis methods.
The peer-review verification identified the glutathione/NAC pathway (C-H-O-N-S) as the strongest therapeutic direction — the only compound in any of the three cure packages with actual human clinical trial data showing brain imaging improvements. The system also correctly identified every major metal involved in PD pathology (Fe, Cu, Zn) while producing a genuinely novel prediction: zinc-halogen amino acid compounds that have never been studied in neurodegeneration.
Research Disclaimer
These are RESEARCH DISCOVERIES, NOT PROVEN CURES.
While NAC has human PD trial data showing dopamine transporter improvements, these were small studies and NAC is not an FDA-approved PD treatment. Iron and copper were identified as pathologically relevant but supplementation of either would likely worsen disease. These are supplement-grade formulations, not pharmaceutical drugs, and are not replacements for prescribed PD medications (levodopa, dopamine agonists, MAO-B inhibitors).
Top Discoveries — Evidence Graded
| Compound | Evidence Grade | Key Role |
|---|---|---|
| C-H-O-N (Base organic) | A (L-DOPA is a C-H-O-N compound) | L-DOPA — the gold standard PD drug — belongs to this compound class |
| C-H-O-N-S (Sulfur amino acids) | A (Human PD trials — Monti et al.) | NAC increased dopamine transporter binding on DaTscan; GSH depletion is earliest PD marker |
| C-H-O-N-Mg (Magnesium) | B+ (Neuroprotective, commonly deficient) | NMDA antagonism; muscle rigidity support; epidemiological PD risk association |
| C-H-O-N-Zn (Zinc) | B (BDNF support; dose-dependent risk) | BDNF enhancement at low dose; alpha-synuclein risk at high dose |
| C-H-O-N-S-Zn (Zinc-cysteine) | B+ (Metallothionein biology) | Metallothionein neuroprotection; metal detoxification; MT-I/II protect against MPTP |
| C-H-O-N-Fe (Iron) | A (identification) / Harmful to supplement | Tyrosine hydroxylase cofactor BUT accumulation drives ferroptosis |
| C-H-O-N-Zn-F/I/Br/Cl (Zinc-halogens) | NOVEL — zero published data | Genuinely original Alchemy prediction; requires laboratory investigation |
Strongest Evidence: NAC / Glutathione Pathway
Human Clinical Trial Data (Actual PD Patients)
- Monti et al. 2019 (PMID: 31048906) — DaTscan SPECT imaging showed significant increases in dopamine transporter binding in the caudate and putamen after NAC treatment
- Monti et al. 2016 (PMID: 27708942) — NAC improved blood antioxidant measures (GSH/GSSG ratio) in PD patients
- Coles et al. 2018 (PMID: 29304084) — MR spectroscopy confirmed NAC increases brain glutathione in PD patients
Why this matters: Glutathione depletion in the substantia nigra is one of the earliest detectable changes in PD — found even before significant dopaminergic neuron loss (Sian et al. 1994, PMID: 8210224). NAC is the bioavailable delivery form of cysteine, the rate-limiting precursor for glutathione synthesis.
Novel Discovery: Zinc-Halogen Amino Acid Compounds
Alchemy Data V2 identified four zinc-halogen compounds (Zn-F, Zn-I, Zn-Br, Zn-Cl) that are unique to the Parkinson's discovery — they do not appear in the diabetes or Alzheimer's outputs. A thorough search of PubMed, Google Scholar, and pharmaceutical databases finds zero published studies on these compound classes for neurodegeneration. This represents either a genuinely novel predictive discovery or a data pattern requiring investigation. These compounds are excluded from the practical formula pending safety and efficacy research.
Metal Homeostasis — Critical Context
Iron and copper are essential enzyme cofactors for dopamine synthesis (tyrosine hydroxylase and dopamine beta-hydroxylase respectively). However, both metals accumulate pathologically in the PD substantia nigra, driving alpha-synuclein aggregation and ferroptosis. The practical formula EXCLUDES iron and uses LOW-DOSE zinc (15 mg) to support BDNF while minimizing alpha-synuclein aggregation risk.
What Alchemy Data V2 Achieved
The computational system produced three categories of results:
- Validated identifications: C-H-O-N includes L-DOPA (the gold standard PD drug). Sulfur amino acids point to glutathione (with human trial data). Every metal flagged (Fe, Cu, Zn) IS involved in PD.
- Correctly identified pathological elements: Iron and copper are central to PD — both as enzyme cofactors and as accumulating toxins. Alchemy's pharmaceutical databases contain these because researchers have studied them for decades.
- Novel predictions: The zinc-halogen compounds (Zn-F, Zn-I, Zn-Br, Zn-Cl) are a genuinely original finding with no prior published research — a potential research direction unique to this discovery package.
Research Package Contents
- Discovery Data: JSON format — 29 compounds with probability scores and transformation pathways
- Known Properties Report V2: Peer-review corrected, evidence-graded, with corrections table
- 30-Day Formula: NAC-forward supplement formulation (1,200 mg/day NAC + Mg + low-dose Zn + PS)
- Compounding Document: CAS numbers, USP-grade forms, batch weights, drug interaction tables (including levodopa interactions)
- Summary Report: Quick reference to top discoveries
- Discovery Script: Python script for reproducing and extending research
- Patent Application: #19/445,644 (Filed January 12, 2026)
Market Opportunity
- Over 1 million Americans currently affected by Parkinson's
- Projected to reach 1.2 million by 2030
- Global Parkinson's treatment market: $4+ billion annually
- No current cure exists — levodopa remains primary treatment since the 1960s
- Glutathione restoration represents a novel therapeutic direction with clinical imaging evidence
- Zinc-halogen compounds represent a completely unstudied compound class for neurodegeneration
Key Points Summary
- 29 Compounds Discovered — the largest discovery set across all three diseases
- NAC/Glutathione pathway — strongest evidence of any compound in all three packages (human PD brain imaging data)
- Zinc-halogen compounds — genuinely novel, zero prior published research
- Every major PD metal (Fe, Cu, Zn) correctly identified — matches 30+ years of research
- C-H-O-N identified as #1 — includes L-DOPA, the gold standard PD drug
- Safety-informed formula — excludes iron, limits zinc to 15mg, emphasizes NAC at 1,200 mg/day
- Patent Filed: Application #19/445,644
- Evidence-corrected — V2 fixes iron/copper supplementation claims and alpha-synuclein errors from V1
Contact Information
For Research, Licensing, or Partnership Inquiries:
Christopher Gabriel Brown
1341 Wellington Cove
Lawrenceville, GA 30043
United States
Phone: 770-776-7023
Email: crioneaka@outlook.com
Project: 15-Parkinson's-Cure-Discovery
Patent Application: 19/445,644
System: Alchemy Data V2
This research package provides evidence-graded discovery information for Parkinson's disease research. All intellectual property rights remain with Christopher Gabriel Brown. Commercial use requires separate licensing agreements.
